Literature DB >> 19619656

Role of EBV in microRNA dysregulation in Burkitt lymphoma.

Giulia De Falco1, Giuseppina Antonicelli, Anna Onnis, Stefano Lazzi, Cristiana Bellan, Lorenzo Leoncini.   

Abstract

Since its discovery as the first human tumor virus, Epstein-Barr virus (EBV) has been implicated in the development of a wide range of B-cell lymphoproliferative disorders, the first being Burkitt lymphoma. However, the exact mechanism by which EBV promotes oncogenesis is still matter of discussion. A role in EBV-mediated transformation has been proposed for a novel described class of small non-coding RNAs, the microRNAs (miRNAs). EBV encodes viral miRNAs, through which it may interfere with the physiological regulation exterted by cellular miRNAs. In addition, EBV-coded proteins may also disturb the well-orchestrated mechanisms of regulation of cellular function. In this review, we will focus on the role of EBV in malignant transformation of Burkitt lymphoma, with a particular insight in the interplay between the virus and cellular miRNAs.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19619656     DOI： 10.1016/j.semcancer.2009.07.003

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN： 1044-579X            Impact factor:   15.707


  17 in total

Review 1.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

2.  MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas.

Authors:  Gabriella Aquino; Laura Marra; Monica Cantile; Annarosaria De Chiara; Giuseppina Liguori; Maria Pia Curcio; Rocco Sabatino; Giuseppe Pannone; Antonio Pinto; Gerardo Botti; Renato Franco
Journal:  Infect Agent Cancer       Date:  2013-09-30       Impact factor: 2.965

3.  The identification of up-regulated ebv-miR-BHRF1-2-5p targeting MALT1 and ebv-miR-BHRF1-3 in the circulation of patients with multiple sclerosis.

Authors:  Y F Wang; D D He; H W Liang; D Yang; H Yue; X M Zhang; R Wang; B Li; H X Yang; Y Liu; Y Chen; Y X Duan; C Y Zhang; X Chen; J Fu
Journal:  Clin Exp Immunol       Date:  2017-03-28       Impact factor: 4.330

Review 4.  miRNAs in the pathogenesis of oncogenic human viruses.

Authors:  Zhen Lin; Erik K Flemington
Journal:  Cancer Lett       Date:  2010-10-12       Impact factor: 8.679

Review 5.  HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.

Authors:  Marta Epeldegui; Elena Vendrame; Otoniel Martínez-Maza
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

6.  Micro-RNA Expression and Function in Lymphomas.

Authors:  Sukhinder K Sandhu; Carlo M Croce; Ramiro Garzon
Journal:  Adv Hematol       Date:  2011-03-22

7.  Molecular profiling of aggressive lymphomas.

Authors:  Maura Rossi; Maria Antonella Laginestra; Anna Gazzola; Maria Rosaria Sapienza; Stefano A Pileri; Pier Paolo Piccaluga
Journal:  Adv Hematol       Date:  2011-11-24

8.  The presence of Epstein-Barr virus significantly impacts the transcriptional profile in immunodeficiency-associated Burkitt lymphoma.

Authors:  Mohsen Navari; Maryam Etebari; Giulia De Falco; Maria R Ambrosio; Davide Gibellini; Lorenzo Leoncini; Pier Paolo Piccaluga
Journal:  Front Microbiol       Date:  2015-06-10       Impact factor: 5.640

9.  Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma.

Authors:  A Onnis; M Navari; G Antonicelli; F Morettini; S Mannucci; G De Falco; E Vigorito; L Leoncini
Journal:  Blood Cancer J       Date:  2012-08-31       Impact factor: 11.037

10.  The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphoma.

Authors:  Maria Raffaella Ambrosio; Mohsen Navari; Lorena Di Lisio; Eduardo Andres Leon; Anna Onnis; Sara Gazaneo; Lucia Mundo; Cristina Ulivieri; Gonzalo Gomez; Stefano Lazzi; Miguel Angel Piris; Lorenzo Leoncini; Giulia De Falco
Journal:  Infect Agent Cancer       Date:  2014-04-14       Impact factor: 2.965
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.